[
  {
    "ts": null,
    "headline": "How Recent Developments Are Reshaping the DexCom Investment Story",
    "summary": "DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven by a modest increase in the discount rate and more cautious revenue growth projections. The revision reflects tempered optimism following the company's latest guidance and earnings results. Stay tuned to learn how you can stay informed on future updates and shifts in DexCom's valuation narrative...",
    "url": "https://finnhub.io/api/news?id=375c7848862c9962fabb6c7f14aadccf4937c8d21f7a784cfe503a7ce2d8b6ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763205036,
      "headline": "How Recent Developments Are Reshaping the DexCom Investment Story",
      "id": 137494907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DXCM",
      "source": "Yahoo",
      "summary": "DexCom's stock narrative has shifted as analysts lower their fair value estimate from $98.40 to $84.96, marking a significant downward revision in the price target. This adjustment is primarily driven by a modest increase in the discount rate and more cautious revenue growth projections. The revision reflects tempered optimism following the company's latest guidance and earnings results. Stay tuned to learn how you can stay informed on future updates and shifts in DexCom's valuation narrative...",
      "url": "https://finnhub.io/api/news?id=375c7848862c9962fabb6c7f14aadccf4937c8d21f7a784cfe503a7ce2d8b6ac"
    }
  }
]